Antimicrobial Susceptibility Testing Market Size, Share 2030

Report Description

The global antimicrobial susceptibility testing market size was around USD 3 million in 2021 and is estimated to reach USD 4 million by 2030, expanding at a CAGR of 5.9% during the forecast period, 2022–2030. The growth of the market is attributed to the rising prevalence of infectious disease epidemics including shigella, neisseria meningitides, neisseria gonorrhoeae, and salmonella typhi. 

Get Free Sample Report

Antimicrobial susceptibility testing (AST) is a laboratory process to identify the correct antimicrobial treatment against microbes. This procedure is performed by medical technologists or researchers to determine which antimicrobials inhibit the growth of the fungi or bacteria causing a specific infection. The antimicrobial susceptibility test determines a microorganism’s susceptibility to antimicrobial treatments by exposing a specific concentration of organism to standardized concentrations of antimicrobial treatments. The result of this test helps a health care practitioner to treat a person’s infection with an effective drug type. Antimicrobial susceptibility testing is done for bacteria, viruses, and fungi. Antimicrobial susceptibility test methods include minimal inhibitory concentration methods and disk diffusion. The minimal inhibitory concentration is determined by agar dilution, broth microdilution, and agar gradient diffusion. Susceptibility is a term used when microorganisms are unable to survive or grow in the presence of one or more antimicrobial drugs or chemicals. Thus, this process is used by researchers for evaluating which antimicrobial treatment is effective against microorganisms.

Antimicrobial susceptibility testing is done to check for antifungal and antiviral species as well as to see if certain antibiotics are effective against bacteria and if they have evolved antibiotic resistance. The outcomes of this test can be used to guide the selection of medications which is effective in the treatment of a disease. Moreover, antimicrobial susceptibility testing assists medical practitioners to evaluate the treatment services offered by clinics, hospitals, and national infectious disease control and prevention programs. The testing establishes the sensitivity of a bacteria, virus, or fungus strain to a panel of antibiotics, antivirals, and antifungals. Various bacterial species are exposed to specific antimicrobials, if the microbe multiplies in the culture, then one can conclude the bacteria is resistant to that antibiotic drug, conversely if the bacteria stop growing then it is susceptible to the specific antibiotic drug. This informative data is given to medical practitioners in the form of the Minimum Inhibitory Concentration (MIC), which is a measure of microorganism resistance or susceptibility to antibiotic drugs. Antibiotic susceptibility testing is done on a regular basis to ensure that antibiotics are effectively utilized.

COVID-19 Impact

The global spread of COVID-19 has negatively impacted the aggregated sales, operations, and delivery & supply chains. Governments across the world implemented national lockdowns, curfews, travel restrictions, shelter-in-place, and isolation measures delaying distributions and affecting supply chains of the necessary instruments and consumables. Moreover, the COVID-19 pandemic has significant impact on the healthcare industry. The growth of bacterial superinfections in ventilated COVID-19 patients is affected by high levels of antibiotic resistance, which in some situations necessitate continued modification of antibiotic therapy.

The COVID-19 pandemic’s impact on antimicrobial resistance surveillance, control, and prevention was investigated by the World Health Organization (WHO) Antimicrobial Resistance (AMR) Surveillance and Quality Assessment Collaborating Centres Network. The article published in 2021, “Impact of the COVID-19 pandemic on the surveillance, prevention, control of antimicrobial resistance: a global survey” specified that health systems have been majorly affected due to the COVID-19 pandemic.

Market Dynamics

The global antimicrobial susceptibility testing market research report presents a complete market overview by focusing on the current market trends, existing drivers, growth opportunities, and emerging challenges that shape the outcome or overall performance of the market during the forecast period, 2022 to 2030.

Get Free Sample Report

Major Drivers:

Increasing incidence of infectious diseases coupled with pandemic events

The research report finds that the increasing incidence of infectious diseases coupled with pandemic events is expected to drive market growth. The epidemic outbreaks are caused by infectious pathogens including Haemophilus influenza, Streptococcus pneumoniae, Neisseria meningitides, Vibrio cholera, and Salmonella serotype. As per the World Malaria Report 2019, an estimated 228 million cases of malaria were diagnosed globally. Furthermore, the report stated that the 19 countries in sub-Saharan Africa and India carried almost 85% of the global malaria burden.   

Current Restraints:

High cost of automated ID/AST systems and stringent regulatory policies

The utilization of automated antimicrobial susceptibility testing systems in laboratories reduces the incubation and detection time. Automated antimicrobial susceptibility testing devices are equipped with highly advanced functionality and features and are priced at premium rates. However, the high cost of these systems is anticipated to hamper the market expansion and reduces the widespread adoption by end-users, especially for small-budget institutions. The stringent regulatory policies and the challenges associated with antimicrobial susceptibility testing are anticipated to hinder the market growth during the forecast period.

Market Opportunities:

Awareness initiatives for antimicrobial resistance and its control

The awareness initiatives for antimicrobial resistance and its control are anticipated to create lucrative opportunities for the market players.  The healthcare industry is becoming aware of the significance of antimicrobial susceptibility testing methods. For instance, Global Sepsis Alliance (GSA), a non-profit organization located in the US, works to support over one million caregivers in more than 70 countries and increase awareness about sepsis and its management. In the US, the CDC create a new website, to increase antimicrobial susceptibility testing awareness and support the early diagnosis, recognition, and treatment of antibiotic resistance. Moreover, government and intergovernmental organizations are implementing plans and efforts to tackle antimicrobial resistance.

Scope of the Report

The global antimicrobial susceptibility testing market report includes an assessment of the market trends, segments, and regional markets. Overview and dynamics have also been included in the report.

Market Segment Insights

Manual antimicrobial susceptibility products segment to expand at a considerable CAGR

On the basis of product type, the antimicrobial susceptibility testing market is segmented into automated laboratory instruments, manual antimicrobial susceptibility testing products, consumables, culture, and growth media. The manual antimicrobial susceptibility testing products segment is further divided into susceptibility testing disks, susceptibility testing plates, and MIC strips. The manual antimicrobial susceptibility segment is projected to expand at a considerable CAGR during the forecast period, due to the increasing incidence of antibacterial resistance, the rising adoption of susceptibility testing disks in emerging countries, and the new product launches.

Get Free Sample Report

Disk diffusion segment to expand at a significant growth rate

Based on method type, the market is divided into ETEST, disk diffusion, genotyping methods, agar dilution, and automated susceptibility testing instruments. The disk diffusion segment is expected to hold a significant share of the market in the coming years. The disk method does not require any special equipment and the provision of categorial results is easily interpreted by all researchers and flexibility in the selection of disks for testing. 

Clinical diagnostics segment to register considerable market share

Based on application, the market is segmented into drug discovery and development, clinical diagnostics, epidemiology, and other applications. The other applications segment is further fragmented into research and academia applications, bioterrorism surveillance, and environmental monitoring. The clinical diagnostics segment is projected to register a considerable share of the market in the coming years, due to the rising prevalance of HAIs, increasing procedural volume of clinical diagnostic tests, and the introduction of various technologically advanced susceptibility testing products.  

Pharmaceutical & biotechnology companies segment to expand at a substantial CAGR

On the basis of end-user, the antimicrobial susceptibility testing market is segregated into pharmaceutical & biotechnology companies, hospital & diagnostic laboratories, and others. The pharmaceutical & biotechnology companies segment is anticipated to expand at a substantial CAGR during the forecast period, owing to availability of the well-equipped facility and skilled technicians, increasing hospital-acquired infections, and initiatives taken by the key players to provide AST products through diagnostic laboratories and hospitals.  

Get Free Sample Report

Asia Pacific is anticipated to constitute a key market share

In terms of regions, the market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. Asia Pacific is expected to constitute a key share of the market during the forecast period, owing to collaborative efforts by the government, health authorities, and medical professionals to combat antimicrobial resistance, high consumption of antibiotics, and rising issues of Methicillin-resistant Staphylococcus aureus and high incidence of sepsis and HIV/AIDS.  

Get Free Sample Report